The Effect and Safety of Tocilizumab Treatment on IRPF
Status:
Recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
This is a prospective study to investigate the treatment response of Tocilizumab on patients
with idiopathic retroperitoneal fibrosis（IRPF）.
Methods: All the patients fulfilling diagnostic criteria of IRPF would be enrolled. The IRPF
patients will accept Tocilizumab or Glucocorticoid monotherapy for 3 months.
Endpoints: The primary endpoint is to investigate the response of Tocilizumab on IRPF
patients; the secondary endpoints include the decrease of inflammatory markers, side effect.